However, as only approximately 15% of breast cancer patients highly overexpress HER-2, and thus benefit from trastuzumab treatment (Spizzo et al, 2002), the majority of breast cancer patients are still in need of IgG1 antibody-based therapies targeting other more widespread antigens. Here, ERBB2 is linked to breast cancer.